Xeris Biopharma Holdings (XERS) Current Assets (2020 - 2026)

Xeris Biopharma Holdings' Current Assets history runs 7 years deep, the most recent figure standing at $251.7 million for Q1 2026.

• Quarterly Current Assets rose 53.94% year-over-year to $251.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $251.7 million (up 53.94% YoY) and the FY2025 annual result came in at $240.3 million, up 43.33% from the prior year.
• Current Assets was $251.7 million for Q1 2026 at Xeris Biopharma Holdings, up from $240.3 million in the prior quarter.
• Across five years, Current Assets topped out at $251.7 million in Q1 2026 and bottomed at $148.9 million in Q3 2022.
• A 5-year average of $179.4 million and a median of $167.7 million in 2024 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2023 — Current Assets retreated 16.35% — and 2026, when it soared 53.94%.
• Xeris Biopharma Holdings' Current Assets stood at $186.8 million in 2022, then dropped by 16.35% to $156.3 million in 2023, then climbed by 7.29% to $167.7 million in 2024, then soared by 43.33% to $240.3 million in 2025, then climbed by 4.73% to $251.7 million in 2026.
• Business Quant data shows XERS's Current Assets at $251.7 million in Q1 2026, $240.3 million in Q4 2025, and $224.0 million in Q3 2025.